Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels  by Heidenreich, Stefan et al.
Kidney International, Vol. 39 (1991), pp. 259-265 
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Medical University-Poliklinik, University of Muenster, Muenster, Germany 
Direct vasopressor effect of recombinant human erythropoietin on renal 
resistance vessels. The contractile properties of recombinant human 
erythropoietin (rHuEPO) on isolated resistance vessels of renal and 
mesenteric vascular beds were studied in an in vitro model using a small 
vessel myograph. Under isometric conditions, rHuEPO caused a con-
traction of this vasculature in a concentration range between 10 U/ml 
and 200 U/m!. A maximal active wall tension of 1.52 ± 0.19 mNlmm was 
obtained under a rHuEPO dose of 200 U/m!. In Ca2+ free solution, the 
pressor response to high rHuEPO-concentrations was attenuated, and 
the response to low rHuEPO concentrations was abolished. In the 
presence of verapamil, phentolamine and saralasin, rHuEPO-induced 
contractions were not affected significantly. A dose-dependent vasodi-
latation of mounted vasculature to acetylcholine (ACh) indicated that 
endothelium remained intact in our preparations. rHuEPO-induced 
vessel contraction was not abrogated after an enzymatical removal of 
endothelium by collagenase, confirming that the described contractile 
responses are endothelial independent. These findings suggest that a 
direct vasopressor effect of rHuEPO on proximal resistance vessels 
may contribute to development of hypertension seen in rHuEPO-
treated hemodialysis patients. 
Erythropoietin (EPO), the primary regulator hormone of red 
blood cell formation, has been shown to be deficient in plasma 
of anemic patients with end-stage kidney disease [1]. By mo-
lecular cloning and expression of a biological active form into 
mammalian cells [2, 3], recombinant human EPO (rHuEPO) is 
now available for treatment of anemic patients with chronic 
renal failure [4, 5]. The main side effect of application to dialysis 
and pre-dialysis patients is the development or aggravation of 
hypertension, which has been partially explained with an in-
crease of blood viscosity [6, 7], a diminished hypoxic vasodi-
latation or an enhanced cardiac output due to a better myocar-
dial oxygenation [8]. The development of hypertension directly 
after application of rHuEPO, however, and in spite of a slow 
increase of hematocrit, suggests that other pressor mechanisms 
may be involved [5, 9,10]. The incidence of hypertension under 
rHuEPO therapy in juvenile and adult dialysis and pre-dialysis 
patients with different circulatory adaptation processes also 
argues against an exclusively hemodynamic basis for develop-
ment of hypertension. In addition, hemodynamic studies on 
dialysis patients under hormone therapy revealed an increase in 
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total and regional peripheral resistance that could not be 
attributed to secondary vasal mechanisms and blood viscosity 
alterations alone [11]. 
In the present study we tested whether rHuEPO displayed a 
direct vasopressor effect on isolated kidney and mesenteric 
resistance vessels of normotensive Wistar-Kyoto rats in vitro. 
The contractile response to rHuEPO was quantified under 
isometric conditions using a small vessel myograph introduced 
and described by Mulvany et al [12, 13]. In this report, we 
demonstrate that rHuEPO exerted a direct vasopressor effect 




Contractility of small resistance vessels was studied in iso-
lated renal and mesenteric vasculature from 30 male, normoten-
sive Wistar-Kyoto rats (weighing 250 to 300 g) using a small 
vessel myograph introduced by Mulvany et al [12, 13]. This 
apparatus is able to determine active force and wall tension of 
vasculature under isometric conditions. The tested vessel is 
mounted by wires between the two vessel supports of the 
apparatus that are facing each other. The right specimen 
support is movably connected to a transducer by a rod to detect 
stretch and compression. The left specimen support is linked to 
a linear slide that is attached to a micrometer to adjust the 
resting wall tension of the vessel. After sacrifice, the abdominal 
cavity was opened and the kidneys and 5 cm of small intestine, 
together with its mesenteric arcade, was removed. A kidney 
was incised from cortex to medulla, washed and kept unfolded 
in cold Krebs-Ringer bicarbonate buffer, pH 7.4. By microdis-
section, renal proximal resistance vessels with internal diame-
ters between 200 and 250 /Lm were prepared from the medulla. 
For preparation of mesenteric arteries, second branch resis-
tance vessels with comparable diameters to renal vessels were 
dissected from the superior mesenteric artery by removing 
adipose tissue and veins. An isolated vessel segment was 
threaded onto two parallel 40 /Lm steel wires which were 
attached to the two specimen supports of the myograph. In the 
myograph chamber, physiological salt solution (PSS) was kept 
constant to 37°C by a heat exchanger and was equilibrated with 
95% O2-5% CO2 to pH 7.4. The myograph was mounted on a 
stage of a microscope so that vascular segment length and 
distances between mounting wires could be measured by a 
micrometer eyepiece. 
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In the beginning of each experiment vessels were succes-
sively stretched in 10 JLm steps up to a maximum wall tension of 
about 1 mNlmm for normalization. An internal circumference 
Lo = 0.9 . LIOO was chosen, where LlOo is an estimate of the 
internal circumference the vessel would have if unmounted and 
relaxed under a transmural pressure of 100 mm Hg. The internal 
circumference LIOO was obtained by the normalization proce-
dure measuring active wall tension under increasing vascular 
circumferences and then plotting the achieved exponential 
curve against an isobar corresponding to 100 mm Hg. The point 
where both lines were crossing gave the LIOO [14]. Lo has been 
shown to represent the internal circumference at which vascu-
lature exerts its maximally active wall tension [15]. After each 
contraction response, vascular segments were washed at least 
three times with 20 ml fresh PSS and allowed to equilibrate for 
30 minutes. 
To check viability, vessels were exposed to PSS containing 
125 mM potassium (K-PSS) for contraction and rejected for 
additional experiments if an active wall tension of 10 mNlmm 
was not achieved. 
Integrity of endothelium was proven by plotting vessel relax-
ation to ACh (1 to 100 nM) after a-adrenergic vasoconstriction 
induced by norepinephrine (1 JLM) in four vessels. 
To determine whether contractile responses to rHuEPO were 
endothelial dependent or independent, endothelial cells of renal 
resistance vessels were enzymatically removed by collagenase 
digestion. In these experiments (N = 5) isolated kidneys were 
perfused with PSS containing 0.2% collagenase (Sigma, Type 
IA) under a constant flow of 5 mllmin for eight minutes at 37°C 
and thereafter with genuine PSS to wash out collagenase 
residues. Small resistance vessels were prepared as described 
above and mounted in the myograph chamber. Vascular pre-
contraction was induced by 1 JLM norepinephrine and the vessel 
response plotted under ACh stimulus. When treatment with 1 to 
100 nM ACh could not induce any relaxation vasculature was 
assumed to be denuded of endothelium. Vessels were exten-
sively washed and equilibrated for 60 minutes in PSS before 
starting exposure to rHuEPO. 
Solutions 
The physiological salt solution (PSS) used for vessel exposi-
tion and contraction studies had the following composition (in 
mM): NaC1119; KCI4.7; NaHC03 25; MgS04 0.6; KH2P04 1.2; 
CaCl2 2.5; Ca EDTA 0.026 and glucose 5.5. To exclude that 
vasopressor effects under rHuEPO were augmented or de-
creased by high ionized Ca concentrations control experiments 
were also made with PSS containing 1.2 mM CaCI2 • In potas-
sium response tests K-PSS was used with an equimolar substi-
tution of KCl for NaCl. Ca2+ -free PSS was as for PSS, but with 
the CaCl2 replaced by 1 mM ethylene glycol bis (,B-aminoethyl-
ether)-N,N'-tetraacetic acid (EGTA). Vessels were pre-equili-
brated in the absence of Ca for 15 minutes. 
Recombinant human erythropoietin (rHuEPO) was provided 
by Dr. T. Brune, Behring-Werke, Marburg, Germany. It had a 
specific activity of 120,000 U/mg (lot no. 345001), and was 
stabilized in a albumin-free phosphate buffer solution. For some 
control experiments, commercially available rHuEPO (Cilag) 
was used. Concentrations of rHuEPO (10 to 200 U/m!) are 
indicated in the Results and in the Figure legends. Verapamil (1 
JLM), saralasin (1 JLM), phentolamine (1 JLM) and indomethacin 







Active wall tension (mNlmm) of 
Renal 
0.43 ± 0.05 
0.70 ± 0.06 
1.52 ± 0.19 
Mesenteric 
vasculature 
0.39 ± 0.06 
0.65 ± 0.08 
NO 
Values are means ± SEM of eight identical experiments. Statistically 
significant differences between wall tension of renal and mesenteric 
vessels were not found. Diameters and segment length of vasculature 
are detailed under Results. NO, not determined. 
(0.5 JLg/ml) were obtained by Sigma Chemical Co. (St. Louis, 
Missouri, USA). Previously we have demonstrated that the 
concentration of 1 JLM used for the blockers was effective in 
completely reversing the vasopressor effects of the respective 
agonists in concentrations eliciting a maximum response. All 
substances were dissolved in PSS, solutions adjusted to pH 7.4, 
equilibrated with 95% O2-5% CO2 and exposed to vessels at 
37°C. All solutions were made fresh for each experiment. 
Analysis of results 
Active force (BF) is defined here as the difference of divisions 
between maximal response during contractions and wall tension 
in PSS immediately before activation, mUltiplied by recorder 
sensitivity a. 
Active wall tension (BT) of vessels is calculated by dividing 
the measured active force by twice the segment length (seg): BT 
= BFI2 . seg. 
Statistics 
In the Figures representative experiments are presented from 
a number of 4 to 8 experiments, as indicated in the legends. In 
Table 1, average values are given as means ± SEM, and 
differences calculated for significance using the two-tailed 
t-test. 
Results 
rHuEPO-induced contraction of small resistance vessels and 
dose response 
For the examination of contractility under rHuEPO expo-
sure, small resistance vessels from renal medulla and mesente-
rium were prepared. In the experiments shown in Figures 1 to 
3 and in Table 1, vasculature had an internal diameter between 
200 and 250 JLm and a segment length between 1.9 and 2.1 mm. 
Because active force is directly plotted by the recorder and only 
original recordings are presented here, the Figures reveal force 
of renal vessels under rHuEPO application. Since active wall 
tension is dependent on segment length of vasculature, for 
statistical evaluation and description of dose-dependency, the 
active all tension is calculated in Table 1. 
Figure lA shows that threshold concentration for a pressor 
response to rHuEPO was 10 Vim!. Spontaneous alterations of 
wall tension were never seen. The maximal pressor response of 
renal vessels was achieved by rHuEPO exposure with 200 Vlml 
and reached an active force of 3.1 mN as indicated in Figure lB. 
Above this concentration a further enhancement of contractility 














oj 2 Fig. 1. Vasopressor effect ofrHuEPO on a ~ 
~ renal small resistance vessel. The threshold 
rHuEPO dose for a contractile response was 
10 U/ml (A) , the maximal response was 
0 obtained under rHuEPO doses of 200 U/ml 
(8). The recordings show typical vascular 
2 min responses out of eight identical experiments . 
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~ ; [ ) E fi / -.... & 
'----
CA2 + -free PSS 
B EPa Epa 
:li ] Fig. 2. Influence of ionized calcium E oj ~ '"'- concentration and Ca depletion on rHuEPO-~ induced vascular contraction. A. [Calo of 1.2 0 p-u.. mM did not abrogate pressor response to 
Ca2 + -free PSS rHuEPO compared to the higher Ca concentration of 2.5 mM used in all other 
experiments (8). Incubation with Ca-free , 
C EPa EGT A reconstituted medium abrogated the 
:li ] EPa rHuEPO-mediated contractile response of E ( ) renal vessels by rHuEPO doses up to 20 Ulml oj under [Calo of 1.2 mM (A) or 2.5 mM (8). ~ ~ Under higher rHuEPO concentrations (50 UI 
ml in C) Ca-depletion led to a diminished 
Ca2 + -free PSS pressor response . This is a typical experiment 
2 min out of eight identical studies. 
was not achieved. In Table 1 the dose-dependency of rHuEPO-
induced contraction is determined as active wall tension, and 
contractility of renal and mesenteric vasculature is compared. 
Under an rHuEPO dose of 20 U/ml, the mean value of pressor 
response was 0.43 ± 0.05 mN/mm for renal vessels. rHuEPO 
doses of 50 U/ml produced a wall tension of 0.70 ± 0.06 
mN/mm, and doses of 200 U/mm produced 1.52 ± 0.19 mN/mm. 
To exclude special effects of rHuEPO on renal arteries, also 
second branch resistance vessels from small intestine mesente-
rium were prepared with a comparable resting tension and with 
nearly identical diameters. The pressor response was in the 
range of renal arteries and did not show significant differences. 
As indicated in the Figure legends and Table I, eight different 
vessels were prepared for determination of threshold and peak 
concentrations and dose dependency. 
Influence of Ca depletion on rHuEPO-induced vessel 
contraction 
Figure 2A shows rHuEPO-induced vessel contraction of 
renal vasculature under 1.2 mM [Ca)o. An active force of 0.95 
mN was registrated with an rHuEPO dose of 20 Ulml. Pre-
equilibration of the mounted vessel in Ca free, EGTA substi-
tuted PSS for 15 minutes completely abrogated the pressor 
response. In Figure 2B an average experiment is demonstrated 
under [Ca]o of 2.5 mM, indicating that slightly higher concen-
trations of ionized [Ca]o do not disturb or magnify pressor 
effects under rHuEPO. Therefore, in all other Figures the 
experiments used 2.5 mM [Ca]o. rHuEPO doses of 50 U/ml and 
higher concentrations produced a force above 1 mN, which was 
attenuated but not completely blocked by Ca-depletion (Fig. 
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Fig. 3. Effect of verapamil, phentolamine and saralasin on rHuEPO-
induced vessel contraction. The contractile response of a renal vessel is 
shown under rHuEPO exposure with 50 Vlml without (A) and with 
simultaneous incubation with verapamil (B), phentolamine (C) and 
saralasin (D), (each dose 1 JLM). The blockers were added to medium 2 
min before rHuEPO stimulus. A representative recording out of five 
identical experiments is shown. 
2B). For determination of the influence of [Ca]o and Ca-
depletion eight different vessels have been used. 
Influence of blockers of vasoactive substances on rHuEPO-
induced vessel contraction 
To further elucidate the mechanisms of rHuEPO-induced 
contraction, we investigated whether the pressor effect was 
mediated by Ca channels or receptors of vasopressor hor-
mones. Figure 3 presents four representative recordings show-
ing the influence of verapamil, phentolamine and saralasin on 
contractions induced by 50 D/ml rHuEPO. Figure 3B indicates 
that the calcium antagonist verapamil did not block rHuEPO-
induced contractility although in most experiments a slight 
mitigation of force, especially in the initial phase, was ob-
served; Statistically relevant differences, however, could not be 
observed. Figures 3C and 3D demonstrate that phentolamine 
and saralasin did not affect the rHuEPO-induced vascular 
response under rHuEPO doses of 50 Dim\. The baseline force 
of the vessel was slightly reduced after application of phentol-
amine (Fig. 3C), probablY by the blockade of intrinsic noradren-
aline deriving from intramural nerves. The recording under 
Figure 3D reveals a transient increase of force after exposure of 
the vessel to saralasin, which can be explained by the intrinsic 
activity of the angiotensin II receptor blocker, saralasin. 
To exclude involvement of endothelial derived arachidonate 
metabolites in rHuEPO-induced pressor responses we also 
preincubated vessels with indomethacin. Contraction to 
rHuEPO was not altered by this treatment (data not shown). 
This finding is in accordance to the data shown below, indicat-
ing that rHuEPO-induced pressor responses were also detected 
in de-endothelialized vasculature. Six different arteries were 
tested for studying the influence of blockers on rHuEPO-
mediated vascular contractions. 
Demonstration of endothelial integrity after vessel mounting 
All experiments showing an rHuEPO-induced vasopressor 
response have primarily been performed with prepared resis-
tance vessels, avoiding an injury of endothelium. To check 
whether endothelium was actually intact after our preparations 
and thus exclude any generation of vasoactive mediators of an 
injured endothelium, relaxation of mounted precontracted ves-
sels to ACh was tested. Figure 4 shows that a renal vessel 
precontracted by 1 JLM of a-adrenergic agonist norepinephrine 
could be relaxed by ACh under concentrations between 1 and 
100 nM. This relaxation by ACh strongly favors the integrity of 
the endothelium according to studies by Furchgott and Za-
wadzki [16]. Four identical experiments were done. 
rHuEPO-induced contraction of renal vessels after removal 
of endothelium 
To elucidate whether rHuEPO-induced contractions have 
direct effects on vascular smooth muscle or are indirectly 
mediated by vasoactive factors released from endothelium, 
renal arterioles were denuded of endothelium by collagenase 
digestion. After perfusion of an isolated kidney by collagenase-
substituted PSS and consecutively preparing resistance vascu-
lature, an artery was pre contracted by norepinephrine. As 
indicated in Figure 5A removal of endothelium was proved by 
missing any relaxation to 1 to 100 nM ACh. The same vessel 
showed a dose-dependent vasopressor response to rHuEPO 
after a 60 minute period of washing and equilibration. Figure 5B 
reflects a pressor response of 0.71 mN to 20 D/ml rHuEPO, 
Figure 5C of 1.09 mN to 50 D/ml rHuEPO without a statistically 
relevant difference to vessels with intact endothelial layer. On 
five different renal arteries endothelial-independent vessel con-
tractions by rHuEPO were tested with equivalent results. 
Discussion 
The present study demonstrates for the first time a direct 
dose-dependent vasopressor effect of rHuEPO on small resis-
tance vessels under isometric conditions. Contraction was 
induced by rHuEPO immediately without time delay. This 
direct response argues against mechanisms requiring de novo 
protein synthesis or generation of secondary vasoactive metab-
olites such as prostaglandins. The demonstration that rHuEPO 
































Fig. 4. After a-adrenergic precontraction of a 
mounted vessel ACh produced a relaxation 
down to concentrations of 1 nM. This relaxing 
effect confirmed integrity of endothelium after 
preparation and mounting of vessels (N = 4) . 
B < ) C ~(--------------7) Fig. 5. After removing the endothelium of the 
vasculature by collagenase digestion, the 
relaxing effect of acetylcholine on a 
precontracted vessel was abolished (A). The 
same vessel further contracted to rHuEPO 
stimulus dose-dependently using 20 Ulml (D) 
and 50 Vim I (e). A typical experiment out of 
five identical studies is shown. 
:I 
:t E ! 
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also induced vasoconstriction in vessels after removing endo-
thelium indicates that rHuEPO directly acts on smooth muscle 
and does not require generation of secondary mediators such as 
arachidonate metabolites, endothelin or other growth factors. 
Since pretreatment of vessels with indomethacin did not abro-
gate rHuEPO-induced vasoconstriction, eicosanoids can be 
widely excluded in the described vasopressor processes. 
rHuEPO-induced contraction showed an initial peak and a 
tonic, permanent contraction as the typical contraction profile . 
Contractions were induced down to threshold concentrations of 
10 Vlml rHuEPO. This concentration is in the range of peak 
serum levels one hour after Lv. rHuEPO administration to 
dialysis patients where rHuEPO levels of over 2 Ulml were 
measured [17, 18J. This dose range for rHuEPO-induced vaso-
pressor responses can also be reconciled with the observation 
that hypertensive events are more frequently seen in patients 
under i.v. rHuEPO therapy when peak serum levels are pro-
duced. Nevertheless, development of hypertension has also 
been observed under smaller serum levels, for instance due to a 
delayed uptake after subcutaneous injection. But in in vitro 
studies a diminished sensitivity of vessels to vasopressors, for 
instance because of preparative manipUlations of vasculature, 
and differences of the resting tension in comparison to in vivo 
conditions cannot be excluded. 
rHuEPO-induced small vessel contractions could not be 
blocked or attenuated by the a-receptor blocker phentolamine 
or the angiotensin II receptor antagonist, saralasin. A direct 
interaction with a- or angiotensin II receptors could be widely 
excluded by these studies. However, our studies suggest an 
influence of rHuEPO on calcium mediated contraction or Ca-
fluxes. Using Ca-free, EGTA-substituted medium for contrac-
tioQ experiments, a markedly reduced response became obvi-
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ous. Under threshold rHuEPO concentrations of 10 or 20 U/ml 
a contraction was inhibited by Ca-depletion; under higher 
concentrations above 20 U/ml the vasopressor response was 
attenuated but not blocked. The calcium blocker verapamil did 
not abrogate rHuEPO-induced contraction, although some in-
fluence on the initial pressor response cannot be excluded 
without reaching statistical significance. These results suggest 
that rJiuEPO-induced contraction might be predominantly me-
diated by Ca channels or fluxes that are not affected by the 
organic calcium blocker verapamil. Other studies, focusing on 
differentiation and proliferation of erythroid progenitor cells, 
have shown a stimulation pftransmembrane calcium fluxes [19] 
and a rise in intracellular free calcium after exposure to 
rHuEPO [20]. An exact elucidation of involved receptors and 
transmembrane processes could not be presented, but the latter 
investigation proposed that elevated cytosolic calcium was 
derived from intracellular sources because the experiments 
were all performed in absence of extracellular Ca. These 
findings concerning the effect of rHuEPO on the activation 
cascade of hematopoietic precursor cells may give a hint to 
intracellular calcium-dependent processes of smooth muscle 
cells sti:mulated by the hormone. 
To exclUde' special effects of rHuf;PO on renal small resis-
tancevessels, parallel studies using mesenteric small vessels 
were conducted. These experiments demonstrate that rHuEPO 
induced vasoconstriction might be a general vessei effect since 
mesenteric vasculature also exerted a contractile response to 
rHuEPO. 
A recent study of London et al [11] on vl:iscular and hemo-
dynamic alterations of dialysis patients under rHuEPO therapy 
favors direct and active vascular regulatiqn processes includi~g 
venoconstriction. This group described a significant decrease in 
left ventricular ejection volumt: with an increase of total periph-
eral resistance by echocardiographic measurements. Venolls 
occlusion plethysmography expr~'ssed a: reduction of musculo-
cutaneous blood flows ~nd an increase in regional peripheral 
resistance. These effects can be explained in part by the 
increase of whole blood viscosity, but the authors discuss a 
direct vascular effect of rHuEPO and also propose a venocon-
striction. The data of our study · support these in vivo findings 
since;: a modest response of venous 'vasculature can easily be 
reconciled with a direct hormonal effect on smooth muscle 
cells. 
In former studies the in vitro model of the isolated perfused 
rat kidney has been used to investigate a possible vasopressor 
capacity of rHuEPO [21]. It has been shown that in a dose of 1 
U/m! EPO was not able to affect the perfusion flow under a 
constant' pressure of 100 mm Hg.These data are not incompat-
ible with ,our findings. In the isolated kidney, intrinsic regula-
tory mechil[~isms, for example' those mediated by the autono-
mous nerve system,or local mediators such as prostanoids, may 
maintain a constallt perfusion flow and conceal a direct vaso-
pressor effect of rHuEPO. Our studies using isolated small 
resistance v<;sselswidely exclude regulatory circuits that may 
be rtOlevant in an isolated kidney or in vivo. In addition, in this 
study lower rHuEPO doses were used in comparison to our 
experiments. ' 
In summary, our investigations suggest direct vasopressor 
effects of rHuEPO on small resistance vasculature by smooth 
muscle cell contractiQn. This vasoactive capacity of rHuEPO 
may contribute to the development of hypertension seen in 
rHuEPO-treated dialysis patients and may amplify or aggravate 
other relevant pathomechanisms of hypertension. 
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